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Abstract
The blood lipid composition (plasma, platelets and leukocytes), platelet membrane fluidity, apolipoproteins A and B in the
plasma of AD patients and control subjects with distinct Apo E genotypes were investigated. No significant differences were
found between the Apo E genotype and the cholesterol, phospholipids, triglycerides and Apo B levels in the plasma;
cholesterol and phospholipids levels in platelet and leukocyte membranes; and platelet membrane fluidity of AD and control
groups. However, the phospholipid levels in the leukocyte membranes of the control subgroup with the genotypes O3/O3 and
O3/O4 and the AD subgroups with the genotypes O2/O3 and O3/O3, O3/O4 and O4/O4 were significantly lower than those observed
in the control subgroup with the genotype O2/O3. Moreover, the cholesterol and phospholipid levels in the platelet membranes
of the AD subgroup with the O2 allele were significantly higher than those in the AD subgroup without the O2 allele and the
control subgroups with and without the O2 allele. A strong correlation was found between cholesterol and phospholipids
levels in the platelet membranes of the AD and control subgroups without the O2 allele, but the residual cholesterol level in
the platelet membranes of the AD subgroup was twice that observed in the control subgroup. Furthermore, the Apo A levels
in the plasma of the AD subgroup with the O3 allele were significantly lower than those observed in the AD subgroup without
the O3 allele and the control subgroup with the O3 allele. The results are discussed in terms of involvement of lipid metabolism
in the etiopathogenesis of AD. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Alzheimer’s disease; Apolipoprotein A metabolism; Apolipoprotein E genotype; Lipid homeostasis ; Membrane £uidity;
Oxidative stress
1. Introduction
Plasma apolipoproteins, namely apolipoprotein A
(Apo A), apolipoprotein B (Apo B), and apolipopro-
tein E (Apo E) are components of several plasma
lipoproteins (chylomicrons, very low-density lipopro-
teins (VLDL), and high-density lipoproteins (HDL)
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where they play a major role in the transport and
redistribution of lipids (such as cholesterol, phospho-
lipids, cholesterol esters, and triacylglycerols) among
various tissues [1].
The gene encoding Apo E (Apo E) is polymorphic
with three major alleles, O2, O3, and O4, and it is a
risk factor for Alzheimer’s disease (AD). The O3 al-
lele is the most common in the general population.
The O4 allele increases the risk of AD and lowers the
age of onset in a dose-dependent manner. Con-
versely, O2 allele decreases the risk and delays AD
onset. Corresponding to the three major Apo E al-
leles, there are three major Apo E isoforms: Apo E2,
Apo E3 and Apo E4. They di¡er only in amino acids
at positions 112 and 158. Apo E2 is the least com-
mon isoform with cysteine at both positions. Apo
E3, the most common isoform, has a cysteine at
112 position and an arginine at 158 position, whereas
Apo E4 presents arginine at both sites [2].
It has been described that the presence of the Apo
E O4 allele is associated with impairment of plastic
neuronal remodeling [3,4] and cholinergic dysfunc-
tion [5^7] in AD patients’ brain tissue, two main
functions which rely on brain lipid homeostasis
[8,9]. Based on these observations it is possible to
hypothesize that brain lipid homeostasis may be se-
lectively compromised in AD patients carrying the O4
allele. This hypothesis is consistent with membrane
defects, such as changes in membrane lipid composi-
tion and £uidity in the brain and peripheral cells of
AD patients [10^19] [20^24].
In the present study, we examine the lipid compo-
sition of the blood (plasma, platelets and leukocytes),
Apo A and Apo B in the plasma, and platelet mem-
brane £uidity of probable AD patients and control
subjects with distinct Apo E genotypes. Membrane
£uidity was evaluated in platelets because they are
used as a peripheral model for the study of central
nervous system (CNS) metabolism in AD [25]. More-
over, it is hypothesized that they may play a role in
the pathophysiology of CNS in AD [26,27]. In fact,
these blood cells carry over 95% of the circulating
Alzheimer’s L-amyloid precursor protein (ALPP)
and release its proteolytic fragments upon activation.
Hence, platelets may be the source of cerebrovascu-
lar amyloid peptides, one of AD’s pathological hall-
marks.
2. Materials and methods
2.1. Selection of patients and controls
Seventy-four AD patients, 42 female and 32 male
(age range, 41^85 years; mean 68.243 þ 9.017 years)
and 35 age-matched healthy subjects free of cognitive
impairment, 18 female and 17 male (age range, 47^84
years; mean 64.971 þ 10.416 years) were retained for
this study.
Patients with dementia met DSM IV [28] and
NINCDS-ADRDA criteria [29] for the diagnosis of
probable AD. They had at least a 1-year history of
cognitive decline con¢rmed by neuropsychological
examination. Neuroradiologic evaluation was also
compatible with degenerative dementia. Laboratory
studies, including thyroid gland function, lues serol-
ogy, vitamin B12, folate levels and CSF study were all
normal.
Forty patients had early AD, with onset of illness
before 65 years of age, and 34 patients su¡ered from
late AD. Global cognitive impairment was assessed
by the Mini-Mental State Examination (MMSE)
[30]. The mean MMSE score of the patients group
was 10.514 þ 7.467 (range, 0^29) and of controls, 30.
Global dementia severity was staged in accordance
with the Clinical Dementia Rating (CDR) [31,32],
where CDR 0 indicates no impairment and CDR
0.5, 1, 2, and 3 indicate questionable, mild, moderate
and severe dementia, respectively. Among the pa-
tients group, 16 subjects (21.6%) were staged as
mild dementia, 30 as moderate dementia (40%) and
the remaining 28 cases as severely demented (37%).
By de¢nition, none of the controls had evidence of
cognitive impairment and all were rated CDR 0 (no
dementia). Family history of dementia, considered
whenever there was an a¡ected ¢rst-degree relative,
was con¢rmed in 15 patients (20.27%). The study
was approved by the Ethics Committee of the Uni-
versity Hospital of Coimbra, and before admission to
the study, a written informed consent was obtained
from all healthy-aged subjects and families of pa-
tients.
2.2. Apo E genotype determination
DNA was prepared from 10 ml of venous blood of
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AD patients and age-matched controls by standard
procedures [33]. Apolipoprotein E genotypes were
analyzed by using polymerase chain reaction (PCR)
and identi¢ed through Cfo I digestion as described
earlier [34] Digested DNA fragments were analyzed
through electrophoresis on 5% agarose gel (Multi-
purpose Agarose, Boehringer Mannheim, Germany)
against a 10-bp ladder (Promega) as marker. Sepa-
rated fragments of DNA were visualized by staining
with ethidium bromide.
2.3. Preparation of plasma, leukocytes and platelets
Plasma, erythrocytes, leukocytes, and platelets
were prepared from blood samples (10 or 20 ml)
collected in tubes containing EDTA or ACD. Plasma
and leukocytes were prepared at room temperature
(or 4‡C when necessary) by centrifugation of the
blood samples (10 ml) collected in EDTA at
200Ug for 10^15 min. After centrifugation, the plas-
ma, the bu¡y coat, and the erythrocytes were col-
lected and put into three separate tubes. The bu¡y
coat, containing the leukocytes, was diluted (2:1)
with PBS, pH 7.4, and the cells were isolated in a
Ficoll gradient after centrifugation at 200Ug for
15 min, as described before [35]. Platelets were pre-
pared according to Marinho et al. [36].
2.4. Lipid composition and membrane £uidity-related
parameters
Lipid composition, and membrane £uidity-related
parameters included the determination of cholesterol,
phospholipid and triglycerides in the plasma, choles-
terol and phospholipid in the platelets and leuko-
cytes, the Apo A and Apo B in the plasma, and
the membrane £uidity in the platelets.
Cholesterol, phospholipid and triglycerides were
assayed in lipid extracts obtained from plasma, plate-
lets, and leukocytes by the method described by
Bligh and Dyer [37], using methanol and chloroform
as organic solvents. The cholesterol, phospholipid,
and triglycerides were assayed using the appropriate
kits commercialized by the Boehringer Mannheim.
The cholesterol, phospholipid and triglyceride levels
in the plasma were expressed in mM, and in the
platelets and leukocytes in mmol g protein31. Apo
A and Apo B in the plasma were measured using the
appropriate reagents commercialized by Beckman-
Immunochemistry Systems, and expressed in mg
dl31.
Platelet membrane £uidity was evaluated on the
basis of the methodology described by Shinitzki
and Barenholz [38], van Blitterswijk et al. [39], and
Kubina et al. [40], using the £uorescent probes di-
phenylhexatriene (DPH) and trimethylamino-diphen-
ylhexatriene (TMA-DPH). The results were ex-
pressed in DPH and TMA-DPH £uorescence
anisotropy (arbitrary units).
2.5. Protein analysis
The protein was estimated by the method of
Lowry et al. [41], using bovine serum albumin as
standard.
2.6. Statistical analysis
One-factor or two-factor ANOVA, was used as
appropriate, to compare biochemical parameters be-
tween AD and control groups for the di¡erent Apo E
genotypes or allele frequencies. Multiple comparisons
with the PLSD Fisher’s test were performed when
signi¢cant results were observed during the ANOVA
[42]. However, due to the unbalanced number of ob-
servations in the group associated with the presence
of the O2 allele the ANOVA results cannot be con-
sidered conclusive, since the probability of a type I
error would depart markedly from 0.05. ANCOVA
[43] was used to compare the cholesterol/phospho-
lipid ratios between AD and control groups without
the O2 allele due to the small sample size associated
with the presence of this allele. Statistical signi¢cance
was set at P6 0.05 for all tests.
3. Results
Table 1 shows the levels of cholesterol, phospho-
lipid, triglycerides, Apo A and Apo B in the plasma
of AD and control groups strati¢ed according to the
Apo E genotype and the presence or absence of the
O3 and O4 alleles. No signi¢cant di¡erences were
found between these biochemical parameters in AD
and control groups strati¢ed according to the Apo E
genotype. However, a signi¢cant di¡erence was
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found between the Apo A levels in the plasma of AD
and control groups strati¢ed according to the pres-
ence of O3 allele. It was observed that the Apo A
levels in the AD subgroup with the O3 allele are sig-
ni¢cantly lower (P6 0.05) than those observed in the
AD subgroup without the O3 allele and the control
subgroup with the O3 allele (one-factor ANOVA,
Fisher PLSD).
Table 2 shows the cholesterol and phospholipid
levels, cholesterol/phospholipid ratio, and DPH and
TMA-DPH £uorescence anisotropy of platelets in
AD and control groups strati¢ed according to the
Apo E genotype and the presence or absence of the
O2 allele. No signi¢cant di¡erences (Ps 0.05) were
found between cholesterol and phospholipid levels
in AD and control groups strati¢ed according to
the Apo E genotype (one-factor ANOVA, Fisher
PLSD). However, the cholesterol and phospholipid
levels in the platelets of the AD subgroup with the O2
allele were signi¢cantly higher (P6 0.05) than those
in the AD subgroup without the O2 allele and the
control subgroup with and without the O2 allele
(one-factor ANOVA, Fisher PLSD). The interde-
pendence relationships between platelet cholesterol
and phospholipid content in AD and control groups
without the O2 allele were tested by using ANCOVA
(co-variance analysis). A strong correlation between
cholesterol and phospholipid was shown in these two
groups (P6 0.001), and the following regression
models were obtained: for the AD subgroup, chol-
esterol = 0.048+0.936Uphospholipid, and for the
control subgroup, cholesterol = 0.024+0.625Uphos-
pholipid, indicating that the variation rate of phos-
pholipids and cholesterol is identical in the platelets
of AD and control groups without the O2 allele.
By comparing these two models, it was observed
that, although not being coincidental, they have
slopes statistically identical (Ps 0.05). The di¡erence
between these two regression models is traduced by
slope intercepts statistically di¡erent (P6 0.01), indi-
cating that the residual cholesterol levels in platelets
of AD and control subgroups without the O2 allele
are signi¢cantly di¡erent. This is con¢rmed by the
intercept values of each one of the models, 0.048
for the AD subgroups and 0.024 for the control sub-
groups, which indicates that the residual cholesterol
level of the AD subgroup without the O2 allele was
twice that observed in the control subgroup.T
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No signi¢cant di¡erences (Ps 0.05) were observed
in platelet membrane £uidity, expressed as £uores-
cence anisotropy (r) DPH (a probe incorporated in
the inner lipid bilayer lea£et) and TMA-DPH (a
probe incorporated in the outer lipid bilayer lea£et)
between AD and control groups strati¢ed according
to the Apo E genotype and the presence or absence
of the O2 allele (one-factor ANOVA, Fisher PLSD).
Table 3 shows the cholesterol and phospholipid
levels and cholesterol/phospholipid ratio in the leu-
kocytes of AD and control groups strati¢ed accord-
ing to the Apo E genotype and the presence or ab-
sence of the O2 allele. No signi¢cant di¡erences were
found between the cholesterol levels in leukocytes of
AD and control groups strati¢ed according to the
Apo E genotype and the presence or absence of the
O2 allele. However, the phospholipid levels in the
control subgroup with the genotypes O3/O3 and O3/
O4 and the AD subgroups with the genotypes O2/O3,
O3/O3, O3/O4 and O4/O4 were signi¢cantly lower
(P6 0.01) than those observed in the control sub-
group with the genotype O2/O3 (one-factor ANOVA,
Fisher PLSD). The same results were obtained when
the AD and control subgroups were strati¢ed ac-
cording to the presence or absence of the O2 allele.
4. Discussion
The results presented in this study showed that the
levels of cholesterol, phospholipids, triglycerides and
Apo B in the plasma (Table 1), the cholesterol and
phospholipids levels in platelet and leukocyte mem-
branes (Table 3) and platelet membrane £uidity (Ta-
ble 2) in AD patients are independent of the Apo E
genotype.
However, the phospholipid levels in leukocyte
membranes of AD patients with the genotypes O2/
O3, O3/O3, O3/O4 and O4/O4 were signi¢cantly reduced
as compared with those observed in control subjects
with the genotype O2/O3 (Table 3), but no changes in
cholesterol levels were observed (Table 3). The de-
crease of phospholipid in leukocytes of AD patients,
without changes of cholesterol, is compatible with
leukocyte membranes degeneration in AD and with
membrane damage induced by oxidative stress
(M.A.S. Fernandes et al., unpublished data).
Changes in cholesterol and phospholipids composi-Ta
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tion of platelet membranes were observed in AD
patients with the O2 allele (genotype O2/O3). In these
patients, the platelet cholesterol and phospholipid
levels were signi¢cantly increased as compared with
those of AD patients without the O2 allele and con-
trol subjects (Table 2). The increase of cholesterol
and phospholipid in the platelets of AD patients car-
rying the O2 allele is compatible with platelet mem-
branes regeneration and with membrane repair fol-
lowing oxidative injury in these AD patients. It may
be related with both the e⁄ciency with which the
Apo E2 isoform accomplish this important process
[1] and with its higher antioxidant activity as com-
pared with Apo E3 and Apo E4 [44]. In turn, the
residual cholesterol level in the platelets of AD pa-
tients without the O2 allele, as evaluated by the inter-
dependence relationships between cholesterol and
phospholipid of platelet membranes in AD patients
and control subjects without the O2 allele (genotypes
O3/O3, O3/O4 and O4/O4), was twice that observed in
control subjects. Two previous studies reported no
changes in total platelet cholesterol or phospholipid
composition of AD patients [13,14], while a signi¢-
cant decrease in the cholesterol content [15] and in
the cholesterol to phospholipid ratio [13] of platelets
in the AD group has been reported.
Evidence for changes in platelet membrane choles-
terol homeostasis of AD patients without the O2 al-
lele also cames from the observation that Apo A
levels in the plasma of AD patients carrying the O3
allele were signi¢cantly decreased as compared with
those observed in AD patients without the O3 allele
and control subjects (Table 1). This result is in gen-
eral agreement with a recently reported study on
Japanese subjects in which the plasma levels of
Apo A-I and apo A-II, the major apolipoproteins
associated with HDL, were signi¢cantly lower in
AD patients than in control subjects, although no
signi¢cant di¡erences in these apolipoproteins were
observed between patients with the E3/4 phenotype
and those with the E3/3 phenotype [45]. The reduc-
tion of the Apo A levels in the plasma of AD pa-
tients may be due to the Apo A-I oxidation induced
by oxidative stress. In fact, there is evidence that
oxidized Apo A-I are more susceptibility to proteo-
lytic degradation than the unoxidized form [46].
Moreover, Apo A-I oxidation reduces the ability of
the apolipoprotein to associate with lipid [46], andTa
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the cellular cholesterol e¥ux mediated by HDL [47].
It has also been reported that the plasma level of the
HDL subfraction of largest size, (HDL2b, mean di-
ameter 10.57 nm), is signi¢cantly decreased in AD
patients as compared with control subjects, but no
signi¢cant di¡erences were observed between AD pa-
tients with the apo E4 phenotype and those with E2/
E3 phenotypes [48]. The changes in the platelet mem-
brane cholesterol homeostasis of AD patients with-
out the O2 allele may be a general feature of the
disease and could be related with the amyloid pre-
cursor protein (APP) processing defect, existing in
AD platelets [26,27]. This APP processing defect re-
sults in reduced soluble APP release and increased
membrane retention of APP on the activated plate-
lets surface and is independent of the Apo E allele
[26,27]. In fact, it was recently reported that the
processing of APP was modulated by changes in cel-
lular content of cholesterol [49^51].
Defects in membrane lipid composition, such as
phospholipids and cholesterol, in the brain of AD
patients have been reported [10^12]. It has also
been described that the presence of Apo E O4 allele
is associated with accumulation of 4-hydroxy-2-
nonenal pyrrole adducts, a marker of lipid peroxida-
tion [52^54]. However, in our study, no association
was found between the presence of the Apo E O4
allele and defects in the blood cells membrane lipid
composition of AD patients.
In conclusion, the blood cells (leukocytes and
platezzlets) membrane lipid homeostasis and plasma
apolipoprotein A metabolism are compromised in
AD patients. The residual platelet membrane choles-
terol and the pathogenesis of AD are associated. A
clear relationship between these parameters and the
Apo E allele could not be established, supporting the
idea that AD is a multifactorial disorder with a com-
plex etiopathogenesis.
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